Cure My Disease

Don't miss your cure!

 Log in / Sign up

Inhaled anxiety drug may lower abuse risk, early study hints

NCT ID NCT00603980

Knowledge-focused Sponsor: Nova Pneuma Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compared the abuse potential of an inhaled version of alprazolam (Staccato) with the standard oral pill in 31 people who had previously abused sedatives. Participants rated how much they liked each form and whether they would take it again. The goal was to see if the inhaled form might be less addictive. Results are preliminary and from a small group, so more research is needed.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
alprazolam (inhaler and oral pill)
What this could lead to
If successful, this could lead to a less addictive way to deliver alprazolam for anxiety or panic attacks.
What could go wrong
This is a small, early-phase study in people with a history of sedative abuse, so results may not apply to the general population. The inhaled form may still carry abuse potential.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

31 people

The number who actually took part.

Start date

Jan 2008

Finished

Jan 2009

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and female subjects between the ages of 18 to 55 years, inclusive, who have a history of substance abuse or dependence on barbiturates and/or benzodiazepine receptor agonists for their intoxicating effects Exclusion Criteria: * Subjects with a significant current psychiatric illness or taking any psychotropic prescription medications for therapeutic uses.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Abuse liability of staccato alprazolam are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Abuse liability of staccato alprazolam

Contacts and locations

Locations

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland, 21224, United States